Home › Companies › Nurix Therapeutics, Inc. › 2025-2026

Nurix Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Nurix Therapeutics, Inc.’s Form 8-K, filed 2026-05-15 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
214Asset managers
1,220Fund votes
2026-05-15Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Nurix Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Nurix Therapeutics, Inc.

These tallies are Nurix Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-15 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Nurix Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-05-15
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Arthur T. Sands, M.D., Ph.D.	63,592,948	--	--	16,334,570	3,819,495	Majority: yes
Elect Director: Roger Dansey, M.D.	79,607,489	--	--	320,029	3,819,495	Majority: yes
Elect Director: Paul M. Silva	59,298,612	--	--	20,628,906	3,819,495	Majority: yes

Source: Nurix Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-05-15 — read the filing on EDGAR.

How asset managers voted at the Nurix Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 214 asset managers that disclosed a Nurix Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Nurix Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99%

The 111 asset managers below cast 99.9% of the shares they voted on this item FOR (40,688,809 for, 14,644 against).

FOR: 40,688,809 (98.8%)AGAINST: 14,644 (0.0%)ABSTAIN: 474,061 (1.2%)NOT VOTED: 352 (0.0%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as dis” at Nurix Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
BlackRock	8,273,653	0	0	For
Redmile Group, LLC	7,902,808	0	0	For
Deep Track Capital, LP	5,198,303	0	0	For
BAKER BROS. ADVISORS LP	4,597,916	0	0	For
Rubric Capital Management LP	2,447,623	0	0	For
PERCEPTIVE ADVISORS LLC	2,307,270	0	0	For
Charles Schwab	1,845,551	0	0	For
ARK ETF Trust	1,632,038	0	0	For
Trails Edge Capital Partners, LP	1,412,367	0	0	For
Northern Trust	659,792	7,040	0	For
Affinity Asset Advisors, LLC	628,444	0	0	For
Handelsbanken Fonder AB	492,298	0	0	For
Kynam Capital Management, LP	0	0	473,485	Abstain
JACOBS LEVY EQUITY MANAGEMENT, INC	358,964	0	0	For
BALYASNY ASSET MANAGEMENT L.P.	325,621	0	0	For
ArrowMark Colorado Holdings LLC	314,762	0	0	For
Foresite Capital Management V, LLC	265,000	0	0	For
Wellington	221,950	0	0	For
WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST	180,000	0	0	For
Integral Health Asset Management, LLC	176,790	0	0	For
QUANTITATIVE MASTER SERIES LLC	164,620	0	0	For
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	163,788	0	0	For
Russell Investments	100,106	0	0	For
Jasper Ridge Partners, L.P.	95,711	0	0	For
ARK Investment Management LLC	94,207	0	0	For

Showing the 25 largest of 111 asset managers. See all 111 in the interactive database.

2. To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

77% fund support · no official result

FOR 76%AGAINST 23%

The 107 asset managers below cast 77% of the shares they voted on this item FOR (37,268,282 for, 11,055,247 against).

FOR: 37,268,282 (76.3%)AGAINST: 11,055,247 (22.6%)ABSTAIN: 534,259 (1.1%)

Largest asset managers voting on “To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclo” at Nurix Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	2,167,834	8,424,312	0	Against
Vanguard	6,115,971	0	0	For
T. Rowe Price	5,470,897	0	0	For
State Street	3,377,058	18,640	0	For
Vestal Point Capital, LP	3,023,716	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,480,162	0	0	For
PICTET ASSET MANAGEMENT SA	2,470,194	0	0	For
Capital Group	0	1,786,654	0	Against
Commodore Capital LP	1,662,871	0	0	For
MUTUAL FUND SERIES TRUST	1,323,464	0	0	For
Amova Asset Management Co., Ltd.	1,186,447	0	0	For
Nuveen	780,321	0	0	For
TIAA	744,345	0	0	For
Candriam S.C.A.	0	0	534,259	Abstain
BRAIDWELL LP	524,296	0	0	For
KENNEDY CAPITAL MANAGEMENT LLC	388,368	0	0	For
Dimensional	385,627	0	0	For
Goldman Sachs	343,774	0	0	For
Woodline Partners LP	325,214	0	0	For
Bessemer Trust CO of Delaware, N.A.	309,450	0	0	For
BESSEMER TRUST CO	307,106	0	0	For
BESSEMER TRUST Co OF FLORIDA	307,106	0	0	For
Bessemer Trust Co of California, N.A.	307,106	0	0	For
Bessemer Trust Co of Nevada, National Association	307,106	0	0	For
Fisher Asset Management, LLC	287,980	0	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

3. Election of Class III Directors: Arthur T. Sands, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD 20%

FOR: 63,592,948WITHHELD: 16,334,570

Nurix Therapeutics, Inc.’s own tally for this item (“Elect Director: Arthur T. Sands, M.D., Ph.D.”): 63,592,948 for, 16,334,570 withheld, per its Form 8-K filed 2026-05-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 103,405,813 outstanding shares: 61% for, 16% withheld (77% of the company cast a for/withheld vote).

The 57 asset managers below cast 100% of the shares they voted on this item FOR (23,121,907 for, 0 against).

FOR 84%ABSTAIN 16%

FOR: 23,121,907 (83.7%)ABSTAIN: 4,503,616 (16.3%)

Largest asset managers voting on “Election of Class III Directors: Arthur T. Sands, M.D., Ph.D.” at Nurix Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	2,167,834	3,564,112	Abstain
Vanguard	5,404,439	7,800	For
BlackRock	4,833,259	0	For
T. Rowe Price	2,265,179	0	For
ARK ETF Trust	1,632,038	0	For
State Street	1,528,323	3,868	For
MUTUAL FUND SERIES TRUST	1,297,893	25,571	For
Charles Schwab	922,609	0	For
Capital Group	893,327	0	For
TIAA	744,345	0	For
Dimensional	0	258,949	Abstain
Equitable	187,038	63,470	For
Goldman Sachs	211,153	0	For
Invesco	170,368	0	For
QUANTITATIVE MASTER SERIES LLC	164,620	0	For
Brighthouse	65,163	32,631	For
CARILLON SERIES TRUST	0	88,158	Abstain
Nationwide	50,533	31,966	For
American Century	0	77,991	Abstain
Northern Trust	70,735	0	For
Lincoln Financial	66,600	1,279	For
Global X	67,374	0	For
John Hancock	30,577	29,298	For
AIG/SunAmerica	0	58,276	Abstain
Columbia Threadneedle	56,135	0	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

4. Election of Class III Directors: Paul M. Silva

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%

FOR: 59,298,612WITHHELD: 20,628,906

Nurix Therapeutics, Inc.’s own tally for this item (“Elect Director: Paul M. Silva”): 59,298,612 for, 20,628,906 withheld, per its Form 8-K filed 2026-05-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 103,405,813 outstanding shares: 57% for, 20% withheld (77% of the company cast a for/withheld vote).

The 57 asset managers below cast 100% of the shares they voted on this item FOR (21,391,262 for, 0 against).

FOR 77%ABSTAIN 23%

FOR: 21,391,262 (77.4%)ABSTAIN: 6,234,261 (22.6%)

Largest asset managers voting on “Election of Class III Directors: Paul M. Silva” at Nurix Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	2,167,834	3,564,112	Abstain
Vanguard	5,400,751	11,488	For
BlackRock	4,833,259	0	For
T. Rowe Price	2,265,179	0	For
ARK ETF Trust	1,632,038	0	For
State Street	1,030	1,531,161	Abstain
MUTUAL FUND SERIES TRUST	1,297,893	25,571	For
Charles Schwab	922,609	0	For
Capital Group	893,327	0	For
TIAA	744,345	0	For
Dimensional	0	258,949	Abstain
Equitable	187,038	63,470	For
Goldman Sachs	211,153	0	For
Invesco	170,368	0	For
QUANTITATIVE MASTER SERIES LLC	164,620	0	For
Brighthouse	65,163	32,631	For
CARILLON SERIES TRUST	0	88,158	Abstain
Nationwide	50,533	31,966	For
American Century	0	77,991	Abstain
Northern Trust	0	70,735	Abstain
Lincoln Financial	0	67,879	Abstain
Global X	46,204	21,170	For
John Hancock	30,577	29,298	For
AIG/SunAmerica	0	58,276	Abstain
Columbia Threadneedle	56,135	0	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

5. Election of Class III Directors: Roger Dansey, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%

FOR: 79,607,489WITHHELD: 320,029

Nurix Therapeutics, Inc.’s own tally for this item (“Elect Director: Roger Dansey, M.D.”): 79,607,489 for, 320,029 withheld, per its Form 8-K filed 2026-05-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 103,405,813 outstanding shares: 77% for, 0.4% withheld (77% of the company cast a for/withheld vote).

The 57 asset managers below cast 100% of the shares they voted on this item FOR (27,625,523 for, 0 against).

FOR 100%

FOR: 27,625,523 (100.0%)

Largest asset managers voting on “Election of Class III Directors: Roger Dansey, M.D.” at Nurix Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Fidelity	5,731,946	For
Vanguard	5,412,239	For
BlackRock	4,833,259	For
T. Rowe Price	2,265,179	For
ARK ETF Trust	1,632,038	For
State Street	1,532,191	For
MUTUAL FUND SERIES TRUST	1,323,464	For
Charles Schwab	922,609	For
Capital Group	893,327	For
TIAA	744,345	For
Dimensional	258,949	For
Equitable	250,508	For
Goldman Sachs	211,153	For
Invesco	170,368	For
QUANTITATIVE MASTER SERIES LLC	164,620	For
Brighthouse	97,794	For
CARILLON SERIES TRUST	88,158	For
Nationwide	82,499	For
American Century	77,991	For
Northern Trust	70,735	For
Lincoln Financial	67,879	For
Global X	67,374	For
John Hancock	59,875	For
AIG/SunAmerica	58,276	For
Columbia Threadneedle	56,135	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

6. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2026.

AUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 57 asset managers below cast 99.9% of the shares they voted on this item FOR (27,625,463 for, 60 against).

FOR: 27,625,463 (100.0%)AGAINST: 60 (0.0%)

Largest asset managers voting on “Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public a” at Nurix Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	5,731,946	0	For
Vanguard	5,412,239	0	For
BlackRock	4,833,259	0	For
T. Rowe Price	2,265,179	0	For
ARK ETF Trust	1,632,038	0	For
State Street	1,532,131	60	For
MUTUAL FUND SERIES TRUST	1,323,464	0	For
Charles Schwab	922,609	0	For
Capital Group	893,327	0	For
TIAA	744,345	0	For
Dimensional	258,949	0	For
Equitable	250,508	0	For
Goldman Sachs	211,153	0	For
Invesco	170,368	0	For
QUANTITATIVE MASTER SERIES LLC	164,620	0	For
Brighthouse	97,794	0	For
CARILLON SERIES TRUST	88,158	0	For
Nationwide	82,499	0	For
American Century	77,991	0	For
Northern Trust	70,735	0	For
Lincoln Financial	67,879	0	For
Global X	67,374	0	For
John Hancock	59,875	0	For
AIG/SunAmerica	58,276	0	For
Columbia Threadneedle	56,135	0	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

Largest Nurix Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Nurix Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 103,405,813 shares outstanding at the time of that meeting.

Top Nurix Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	BlackRock	8.00%
2	Redmile Group, LLC	7.64%
3	Deep Track Capital, LP	5.03%
4	BAKER BROS. ADVISORS LP	4.45%
5	Rubric Capital Management LP	2.37%
6	PERCEPTIVE ADVISORS LLC	2.23%
7	Charles Schwab	1.78%
8	ARK ETF Trust	1.58%
9	Trails Edge Capital Partners, LP	1.37%
10	Northern Trust	0.64%

Reported Nurix Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Nurix Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	8.63%	13F
Redmile Group, LLC	8.49%	13G
Vestal Point Capital, LP	7.78%	13G
Deep Track Capital, LP	7.48%	13G
Baker Bros. Advisors LP	7.28%	13G
Rubric Capital Management LP	6.99%	13G
Vanguard Group	5.75%	13F
FMR (Fidelity)	5.36%	13F
State Street	4.97%	13F
Morgan Stanley	4.72%	13F

Percentages above are of 103,405,813 shares outstanding, as reported by Nurix Therapeutics, Inc. on its Form 10-Q dated 2026-04-01 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Nurix Therapeutics, Inc.’s 10-Q dated 2026-04-01. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Nurix Therapeutics, Inc.'s shareholder meeting held 2026-05-15, in the 2025-2026 proxy season, 214 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,220 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Nurix Therapeutics, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — the reporting funds cast 99.9% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Nurix Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).